Cymabay Therapeutics

CBAY

시가총액 US$37.3억

MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDA MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDA

CymaBay Therapeutics Inc. (CBAY) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago.

Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.

-  Seladelpar demonstrated normalization of liver biomarkers and significant reductions across three measures of patient-reported itch vs. placebo -  NEWARK, Calif.

NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to three employees on February 16, 2024 (the “Grant Date”) in connection with the employees' commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualified stock options to purchase an aggregate of 99,000 shares of CymaBay common stock as inducements material to the employees entering into employment with CymaBay in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grants.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CymaBay Therapeutics, Inc. (NasdaqGS: CBAY) to Gilead Sciences, Inc. (NasdaqGS: GILD). Under the terms of the proposed transaction, shareholders of CymaBay will receive $32.50 in cash for each share of CymaBay that they own. KSF is seeking to determine whether this consideration and the process that led to it.

Shares of CymaBay Therapeutics (CBAY) soared to an all-time high Monday after Gilead Sciences (GILD) announced it's buying the developer of medicine for liver and other chronic diseases for $4.3 billion.

MILWAUKEE , Feb. 12, 2024 /PRNewswire/ -- Ademi LLP is investigating CymaBay (Nasdaq: CBAY)  for possible breaches of fiduciary duty and other violations of law in its transaction with Gilead. Click here to learn how to join the https://www.ademilaw.com/case/cymabay-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

CymaBay (NASDAQ: CBAY ) stock is rising higher on Monday after the clinical-stage biopharmaceutical company announced an acquisition agreement with Gilead Sciences (NASDAQ: GILD ). That deal has Gilead Sciences agreeing to acquire CymaBay for $4.3 billion.

CymaBay Therapeutics shares jumped nearly 25% and hit a new record high in early trading after the clinical-stage biopharmaceutical company agreed to be acquired by Gilead Sciences for $4.3 billion.